These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Prevalence of BRCA mutations among women with triple-negative breast cancer (TNBC) in a genetic counseling cohort. Greenup R; Buchanan A; Lorizio W; Rhoads K; Chan S; Leedom T; King R; McLennan J; Crawford B; Kelly Marcom P; Shelley Hwang E Ann Surg Oncol; 2013 Oct; 20(10):3254-8. PubMed ID: 23975317 [TBL] [Abstract][Full Text] [Related]
3. Prevalence and oncologic outcomes of BRCA 1/2 mutations in unselected triple-negative breast cancer patients in Korea. Ryu JM; Choi HJ; Kim I; Nam SJ; Kim SW; Yu J; Lee SK; Choi DH; Park YH; Kim JW; Seo JS; Park JH; Lee JE; Kim SW; Breast Cancer Res Treat; 2019 Jan; 173(2):385-395. PubMed ID: 30350268 [TBL] [Abstract][Full Text] [Related]
4. Prospective Evaluation of Universal Emborgo TS; Saporito D; Muse KI; Barrera AMG; Litton JK; Lu KH; Arun BK JNCI Cancer Spectr; 2020 Apr; 4(2):pkaa002. PubMed ID: 32211581 [TBL] [Abstract][Full Text] [Related]
5. Limited family structure and triple-negative breast cancer (TNBC) subtype as predictors of BRCA mutations in a genetic counseling cohort of early-onset sporadic breast cancers. Zugazagoitia J; Pérez-Segura P; Manzano A; Blanco I; Vega A; Custodio A; Teulé A; Fachal L; Martínez B; González-Sarmiento R; Cruz-Hernández JJ; Chirivella I; Garcés V; Garre P; Romero A; Caldés T; Díaz-Rubio E; de la Hoya M Breast Cancer Res Treat; 2014 Nov; 148(2):415-21. PubMed ID: 25342642 [TBL] [Abstract][Full Text] [Related]
6. Germline BRCA mutation evaluation in a prospective triple-negative breast cancer registry: implications for hereditary breast and/or ovarian cancer syndrome testing. Sharma P; Klemp JR; Kimler BF; Mahnken JD; Geier LJ; Khan QJ; Elia M; Connor CS; McGinness MK; Mammen JM; Wagner JL; Ward C; Ranallo L; Knight CJ; Stecklein SR; Jensen RA; Fabian CJ; Godwin AK Breast Cancer Res Treat; 2014 Jun; 145(3):707-14. PubMed ID: 24807107 [TBL] [Abstract][Full Text] [Related]
7. Increasing referral of at-risk women for genetic counseling and BRCA testing using a screening tool in a community breast imaging center. Arun BK; Peterson SK; Sweeney LE; Bluebond RD; Tidwell RSS; Makhnoon S; Kushwaha AC Cancer; 2022 Jan; 128(1):94-102. PubMed ID: 34424535 [TBL] [Abstract][Full Text] [Related]
8. Promoters of BRCA testing under insurance coverage for non-metastatic breast cancer patients in Japan: a retrospective cohort study. Taji T; Odan N; Kataoka Y; Ikeda M; Yamaguchi A; Suzuki E; Suwa H Breast Cancer; 2023 Mar; 30(2):309-314. PubMed ID: 36547869 [TBL] [Abstract][Full Text] [Related]
9. Frequency of germline pathogenic variants in breast cancer predisposition genes among young Turkish breast cancer patients. Isiklar AD; Aliyeva L; Yesilyurt A; Soyder A; Basaran G Breast Cancer Res Treat; 2023 Nov; 202(2):297-304. PubMed ID: 37615792 [TBL] [Abstract][Full Text] [Related]
10. Adherence Patterns to National Comprehensive Cancer Network Guidelines for Referral of Women With Breast Cancer to Genetics Professionals. Stuckey A; Febbraro T; Laprise J; Wilbur JS; Lopes V; Robison K Am J Clin Oncol; 2016 Aug; 39(4):363-7. PubMed ID: 24710121 [TBL] [Abstract][Full Text] [Related]
11. Outcome of triple-negative breast cancer in patients with or without deleterious BRCA mutations. Bayraktar S; Gutierrez-Barrera AM; Liu D; Tasbas T; Akar U; Litton JK; Lin E; Albarracin CT; Meric-Bernstam F; Gonzalez-Angulo AM; Hortobagyi GN; Arun BK Breast Cancer Res Treat; 2011 Nov; 130(1):145-53. PubMed ID: 21830012 [TBL] [Abstract][Full Text] [Related]
12. High prevalence and predominance of BRCA1 germline mutations in Pakistani triple-negative breast cancer patients. Rashid MU; Muhammad N; Bajwa S; Faisal S; Tahseen M; Bermejo JL; Amin A; Loya A; Hamann U BMC Cancer; 2016 Aug; 16(1):673. PubMed ID: 27553291 [TBL] [Abstract][Full Text] [Related]
14. Impact of BRCA Mutation Status on Survival of Women With Triple-negative Breast Cancer. Yadav S; Ladkany R; Yadav D; Alhalabi O; Khaddam S; Isaac D; Cardenas PY; Zakalik D Clin Breast Cancer; 2018 Oct; 18(5):e1229-e1235. PubMed ID: 29402697 [TBL] [Abstract][Full Text] [Related]
15. Uptake of testing for germline Stearnes G; Nichols CB; Schofield L; O'Sullivan S; Pachter N; Cohen PA Int J Gynecol Cancer; 2019 Jul; 29(6):1038-1042. PubMed ID: 31101686 [TBL] [Abstract][Full Text] [Related]
16. Adherence patterns to National Comprehensive Cancer Network (NCCN) guidelines for referral to cancer genetic professionals. Febbraro T; Robison K; Wilbur JS; Laprise J; Bregar A; Lopes V; Legare R; Stuckey A Gynecol Oncol; 2015 Jul; 138(1):109-14. PubMed ID: 25933682 [TBL] [Abstract][Full Text] [Related]
17. Recognizing BRCA gene mutation risk subsequent to breast cancer diagnosis in southwestern Ontario. Vanstone M; Chow W; Lester L; Ainsworth P; Nisker J; Brackstone M Can Fam Physician; 2012 May; 58(5):e258-66. PubMed ID: 22734169 [TBL] [Abstract][Full Text] [Related]
18. Predictive Factors for BRCA1 and BRCA2 Genetic Testing in an Asian Clinic-Based Population. Wong ES; Shekar S; Chan CH; Hong LZ; Poon SY; Silla T; Lin C; Kumar V; Davila S; Voorhoeve M; Thike AA; Ho GH; Yap YS; Tan PH; Tan MH; Ang P; Lee AS PLoS One; 2015; 10(7):e0134408. PubMed ID: 26221963 [TBL] [Abstract][Full Text] [Related]
19. Referral patterns for genetic counselling of women diagnosed with tubo-ovarian or peritoneal high-grade serous carcinoma (HGSC) within the Auckland Gynaecological Oncology Centre. Burling MJ; Gamet K; Eva L; Tan AL Aust N Z J Obstet Gynaecol; 2019 Jun; 59(3):444-449. PubMed ID: 30883681 [TBL] [Abstract][Full Text] [Related]
20. Current guidelines for BRCA testing of breast cancer patients are insufficient to detect all mutation carriers. Grindedal EM; Heramb C; Karsrud I; Ariansen SL; Mæhle L; Undlien DE; Norum J; Schlichting E BMC Cancer; 2017 Jun; 17(1):438. PubMed ID: 28637432 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]